Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  childhood cancer
Stage/Subtype:  childhood cancer
Results 1-25 of 550 for your search:
Start Over
Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Status: Active
Phase: Phase IV
Type: Treatment
Age: 17 and under
Trial IDs: CDR0000667369, NCI-2014-02026, EU-21011, EUDRACT-2007-004092-19, EURONET-PHL-LP1, NCT01088750
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Status: Active
Phase: Phase IV
Type: Treatment
Age: Any age
Trial IDs: CRAD001C2X01B, NCI-2013-01151, NCT01789281
Peripheral Blood Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 70 and under
Trial IDs: MT2006-13, NCI-2010-02369, 0607M89052, UMN-MT2006-13, NCT00630565
Radiation Therapy with or without Combination Chemotherapy or Pazopanib Hydrochloride before Surgery in Treating Patients with Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 and over
Trial IDs: ARST1321, NCI-2014-01340, NCT02180867
A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
Status: Temporarily closed
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 471501, NCI-2016-01887, NCT02956122
Combination Chemotherapy in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 1 to 18
Trial IDs: TOT17, NCI-2017-00582, NCT03117751
Combination Chemotherapy and Total Body Irradiation in Treating Patients with Fanconi Anemia Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 17 and under
Trial IDs: MT2006-05, NCI-2017-01078, NCT00352976
Chemotherapy and Radiation Therapy in Treating Young Patients with Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: ACNS0332, NCI-2009-00336, CDR0000511991, COG-ACNS0332, NCT00392327
Total Body Irradiation and Combination Chemotherapy before Donor Progenitor Cell Transplant in Treating Younger Patients with Hematologic Malignancies
Status: Active
Phase: Phase III
Type: Treatment
Age: 21 and under
Trial IDs: SCT 0307, NCI-2015-00131, 2007-13121, CMH SCT 0307, NCT00619879
Risk-Based Therapy in Treating Younger Patients with Newly Diagnosed Liver Cancer
Status: Active
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 21 and under
Trial IDs: AHEP0731, NCI-2011-01975, CDR0000654889, COG-AHEP0731, NCT02265692, NCT00980460
Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 0 to 21
Trial IDs: SJBC3, NCI-2011-01251, NCI-2010-00129, NCT01046825
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients with Newly Diagnosed Ependymoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ACNS0831, NCI-2011-02029, CDR0000668560, COG-ACNS0831, NCT01096368
Risk-Adapted Chemotherapy in Treating Younger Patients with Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 1 to < 10
Trial IDs: AALL0932, NCI-2011-02599, CDR0000683227, COG-AALL0932, NCT01190930
Combination Chemotherapy in Treating Patients with Non-Metastatic Extracranial Ewing Sarcoma
Status: Temporarily closed
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1031, NCI-2011-02611, CDR0000687639, COG-AEWS1031, NCT01231906
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981
Assessing Compliance with Mercaptopurine Treatment in Younger Patients with Acute Lymphoblastic Leukemia in First Remission
Status: Active
Phase: Phase III
Type: Behavioral study, Biomarker/Laboratory analysis, Educational/Counseling/Training
Age: 12 to 20
Trial IDs: ACCL1033, NCI-2012-00105, CDR0000721559, NCT01476852, COG-ACCL1033, NCT01503632
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)
Status: Active
Phase: Phase III
Type: Prevention
Age: 15 and over
Trial IDs: GHRT01, NCI-2014-02097, NCT01479283
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1331, NCI-2014-00631, COG-AALL1331, NCT02101853
Combination Chemotherapy with or without Bortezomib in Treating Younger Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 30
Trial IDs: AALL1231, NCI-2014-00712, NCT02112916
Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Hodgkin Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Supportive care, Treatment
Age: 18 and younger
Trial IDs: AHOD1331, NCI-2014-01223, NCT02166463
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients with Non-high Risk Neuroblastoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 17 months and under
Trial IDs: ANBL1232, NCI-2014-00677, NCT02176967
Combination Chemotherapy with or without Ganitumab in Treating Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1221, NCI-2014-02380, NCT02306161
Start Over